PT - JOURNAL ARTICLE AU - Jingjie Zhang AU - Wanchun Zhang AU - Xiaomin Li AU - Le Ma TI - Comparative research on<sup>99m</sup>Tc-rituximab and <sup>99m</sup>Tc- sulfur colloid in sentinel lymph nodemappingof breast cancer DP - 2018 May 01 TA - Journal of Nuclear Medicine PG - 1273--1273 VI - 59 IP - supplement 1 4099 - http://jnm.snmjournals.org/content/59/supplement_1/1273.short 4100 - http://jnm.snmjournals.org/content/59/supplement_1/1273.full SO - J Nucl Med2018 May 01; 59 AB - 1273Objectives: Currently, filtered 99mTc-sulfur colloid (99mTc-SC) is widely used for sentinel node (SLN) mapping in breast cancer. It is a non-specific agent, migrating to more secondary echelon nodes. 99mTc-rituximab is a specific binding radiopharmaceutical that targets CD20, which is highly expressed on the surface of B lymphocytes. The principle is the antigenic antibody-specific response, if the sentinel lymph nodes are not saturated, the secondary lymph nodes won't accumulate. The purpose of this study is to verify that 99mTc-rituximab identities the fewer secondary lymph nodes, compared to 99mTc-SC.Method: By using self-controlled study on the same patient, the patients was randomly injected 1mCi/1ml of 99mTc-rituximab and 1.5mCi/1.5ml 99mTc-SC, intervals of two days, at the 6-and 12-oclock positions by using an subareolar technique. After 2 hours of each injection, the planar imaging and fusion tomography of sentinel lymph node were performed. Results: 25 women with breast cancer were enrolled in this study from August 28, 2016 to August 23, 2017. For each of the patients themselves, 99mTc-rituximab identified fewer or the same number of SLNs, compared to 99mTc-SC. Both of them achieved higher identification rate, were 96%. Both of the two tracers was failed to detect SLNs in one patients, who performed sentinel lymph node biopsy after neoadjuvant chemotherapy. The total number of SLNs identified by 99mTc-rituximab and 99mTc-SC were respectively 64(average, 2.78), 78(average, 3.39), the difference had statistical significance(paired sample t test, P = 0.013 &lt;0.05). By performing tomography fusion imaging to locate SLNs, we found that 64 SLNs were detected by both 99mTc-rituximab and 99mTc-SC, for 82.05% concordance.Conclusions:The results of this study showed that both 99mTc-rituximab and 99mTc-SC has higher SLN identification rate. Furthermore, 99mTc-rituximab detect fewer distal lymph nodes, compared to 99mTc-SC, suggesting that a receptor-binding mechanism of SLN identification may enhance performance of targeting the true SLNs. Key words:Breast cancer; Sentinel lymph node mapping; Radiopharmaceuticals;